SynthesisNeurosurgical review2025
Diagnostic and prognostic role of serum/plasma and CSF amyloid beta peptide levels in traumatic brain injury: a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloid beta (Aβ) peptides, particularly Aβ1-40 and Aβ1-42, have been implicated in TBI pathology as potential biomarkers for diagnosis and prognosis. This systematic review and meta-analysis aimed to evaluate differences in Aβ levels between TBI and non-TBI populations and their prognostic utility in both acute and chronic phases of TBI. A systematic search of MEDLINE, Scopus, and Web of Science was conducted up to October, 2024, with an updated search in July 2025. Studies assessing Aβ1-40 or Aβ1-42 in cerebrospinal fluid (CSF) or plasma of adults with TBI were included. Risk of bias was assessed using the Newcastle-Ottawa Scale. A random-effects meta-analysis was performed for between-group comparisons, with subgroup analyses based on biological compartment and sampling interval. 25 studies were included in the review and 11 underwent quantitative synthesis. Qualitative evaluation of studies suggested a positive correlation between Aβ1-42 and neurological status in moderate to severe TBI but not mild TBI or concussion. Plasma Aβ1-42 levels were significantly elevated in TBI patients within 24 h post-injury (SMD:0.91, 95%CI: [0.15-1.66 No significant differences were observed in CSF (SMD:-0.37, 95%CI: [-0.88-0.15]) or plasma Aβ1-42 (SMD:0.09, 95%CI: [-0.07-0.26]) or Aβ1-40 (SMD:0.10 95%CI: [-0.25-0.44]) levels beyond the first year following TBI. Aβ peptides, particularly Aβ1-42, appear to change acutely in plasma post-TBI but show no consistent long-term alterations in either plasma or CSF. The limited and heterogeneous evidence suggests only modest prognostic potential, with no current support for their clinical use as reliable biomarkers for diagnosis or prognosis in TBI. Further large-scale, standardized studies are warranted.
Indexed as
Identifiers
41075016What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.